Peroxisome proliferator-activated receptor ␥ (PPAR␥) is a member of the nuclear receptor superfamily that has been implicated to play a possible role in adipocyte differentiation (34, 73, 82) , insulin sensitization (42, 51, 61) , and tumor suppression (11, 14, 25, 37, 43, 57, 77, 88) . Ligands for PPAR␥ include modified fatty acids, members of the prostanoid family, linoleic acid derivatives (38, 39, 58) , and synthetic insulinsensitizing thiazolidinedione compounds (TZDs) such as BRL-49653 (rosiglitazone), pioglitazone, and troglitazone (28, 29, 38, 39, 58) .
PPAR␥ is abundantly expressed in adipose tissue and at lower levels in T cells, neutrophils, epithelial cells, smooth muscle cells, and macrophages (19, 48, 81) . The discovery of high levels of PPAR␥ protein expression in the foam cells of atherosclerotic lesions (53, 71) has led to intensive research efforts to identify possible roles of PPAR␥ in regulating cholesterol flux in macrophages and to better understand the possible effects of TZDs on the development of atherosclerosis. With regard to cholesterol uptake, the scavenger receptor, CD36, was demonstrated to be a direct target gene of PPAR␥ in macrophages (15, 56, 58, 87) . Recent studies have shown, however, that neither treatment of macrophages with TZDs (56) nor mutation of the PPAR␥ gene (15) significantly alters oxLDL uptake. Likewise, the basal expression of other scavenger receptors believed to be involved in the uptake of cholesterol, including SR-A and SR-B1, were unaffected by deletion of the PPAR␥ gene in macrophages (15, 56) .
ABCA1, a member of the ATP-binding cassette (ABC)-transporter family, is involved in the control of high-density lipoprotein (HDL) and apolipoprotein A1 (apoA1)-mediated cholesterol efflux from macrophages (12, 50, 63) . Loss-of-function mutations in the ABCA1 gene in Tangier's patients is marked by severe accumulation of cholesterol in macrophages and other tissues, including the tonsils, liver, spleen, and mucosa (9, 12, 32, 75) , suggesting that ABCA1 activity plays an integral role in influencing cellular cholesterol transport (64) . ABCG1 may also play a role in cholesterol efflux, though its role is not well defined (40) . PPAR␥ was recently shown to induce the expression of the cholesterol tranporter, ABCA1, in macrophages through a transcriptional cascade mediated by the nuclear receptor, LXR␣ (16, 21, 79, 91) . Consistent with this PPAR␥-LXR␣-ABCA1 pathway, TZDs were shown to enhance cholesterol efflux from wild-type macrophages, while PPAR␥-deficient macrophages were refractory to the effect of TZDs and also exhibited lowered basal levels of cholesterol efflux (16) . Moreover, transplantation of PPAR␥-null bone marrow into mice lacking low-density lipoprotein receptor (LDLr-null mice) resulted in a significant increase in atherosclerotic lesion size. The implication of these findings is that PPAR␥ exerts antiatherogenic effects by facilitating the removal of cholesterol from macrophages via cholesterol transporter proteins such as ABCA1.
Several lines of evidence indicate that apoE is also an important determinant of atherosclerosis and regulator of cholesterol efflux in macrophages (5, 6, 22, 24, 41, 54, 66, 96, 97) . apoE-null macrophages exhibit markedly lowered cholesterol efflux to HDL3 and lipid-free apolipoproteins in mouse peritoneal macrophages (47) . The transplantation of bone marrow derived from apoE-null mice into the LDLr-null background resulted in a significant increase in atherosclerotic lesion size compared to controls (26) . Conversely, transplantation of bone marrow from wild-type mice into apoE-null mice reduced cholesterol levels in plasma and slowed the progression of atherosclerosis (10, 52) . Likewise, macrophage-specific expression of human apoE in apoE-null mice reduces atherosclerosis (7) . These results suggest that attenuation of apoE expression in bone marrow and differentiated cells derived from progenitor cells in bone marrow (including macrophages) is sufficient to cause the phenotype. Apart from effects on cholesterol flux, apoE overexpression in mice has also been shown to lower levels of isoprostane, an in vivo marker of oxidative stress (86) , which is believed to contribute to the development of atherosclerosis (8, 69, 94) .
A number of previous studies examining the role of PPAR␥ in regulating lipid flux in macrophages have been performed by using macrophage cancer cell lines and macrophages derived from embryonic stem (ES) cells. In the latter, wild-type and PPAR␥-null ES cells were induced to differentiate into macrophages in vitro by using a two-stage process involving initial differentiation of ES cells into embryoid bodies and subsequent differentiation into monocytes and macrophages in the presence of interleukin-3 and macrophage colony-stimulating factor 1 (16, 56) . To a similar end, macrophages have been isolated from chimeric mice that were generated by injection of PPAR␥-null ES cells into wild-type blastocysts (56) . In these mice, the contribution of PPAR␥-deficient cells to the macrophage lineage was demonstrated, suggesting that PPAR␥ is not required for macrophage differentiation in vivo. Moreover, the expression of several macrophage-specific markers was shown to be similar in macrophages derived from both wild-type and chimeric mice (56) . Despite this, it is noted that both the in vivo or in vitro differentiation of macrophages from ES cells occurs in the absence of the PPAR␥ gene. Given that a number of PPAR␥ target genes are expressed in macrophage precursor cells (27, 35, 85, 87) , the possibility remains that ES cellderived macrophage populations, while similar in terms of cell numbers, do not retain all of the phenotypic characteristics and physiological pathways (other than those tested) associated with normal macrophages. Indeed, the in vitro differentiation process itself may alter the expression of several key macrophage proteins involved in cholesterol flux, since macrophage colony-stimulating factor 1 was shown to regulate SR-A and CD36 expression (23, 95) .
To circumvent such problems, a PPAR␥ conditional knockout mouse containing the Cre recombinase gene under the control of the MX promoter was developed. Despite some constitutive expression of the MX-Cre transgene, the majority of thioglycolate-elicited peritoneal macrophages from PPAR␥-MXCre ϩ mice maintain an intact gene for PPAR␥, suggesting that essentially normal development and/or differentiation of the myeloid lineage occurs. Induction of Cre recombinase and the ensuing loss of the targeted PPAR␥ exon, resulted in marked reductions in basal and troglitazone-stimulated expression of the genes encoding lipoprotein lipase (LPL), CD36, LXR␣, and ABCG1 in thioglycolate-elicited peritoneal macrophages. Reductions in the basal levels of apoE mRNA in macrophages and apoE protein in total plasma and HDL were also observed in pIpC-treated PPAR␥-MXCre ϩ mice. Further, basal cholesterol efflux from cholesterol-loaded macrophages to HDL was significantly reduced after disruption of the PPAR␥ gene. Surprisingly, and in sharp contrast to recent findings by using ES cell-derived macrophages (16, 18) , troglitazone inhibited ABCA1 expression (whereas other TZDs, such as rosiglitazone, ciglitazone, and pioglitazone, had little effect) and cholesterol efflux in both PPAR␥-deficient and control macrophages, indicating that troglitazone can exert paradoxical effects on cholesterol homeostasis that are independent of PPAR␥. Together, these data indicate that PPAR␥ plays an important role in the regulation of cholesterol homeostasis by controlling the expression of a network of genes that mediate cholesterol efflux from cells and its transport in plasma.
MATERIALS AND METHODS
Reagents. Oxysterols (Sigma, St. Louis, Mo.), dexamethasone (Sigma), troglitazone (Sankyo Research Laboratories, Fukuroi, Japan), rosiglitazone (GlaxoSmithKline, Research Triangle Park, N.C.), ciglitazone (Biomol Research Laboratories, Plymouth Meeting, Pa.), and pioglitazone (Takeda Chemical Industries, Ltd., Osaka, Japan) were dissolved in dimethyl sulfoxide (DMSO; Sigma).
Targeting vector and generation of PPAR␥ conditional-null mice. A mouse ES-129 P1 genomic library (Genome Systems, St. Louis, Mo.) was screened with the mouse PPAR␥ cDNA (17) . A 4.5-kb HindIII fragment containing exons 1 and 2 of the mouse PPAR␥ gene was subcloned into a modified pGEM-3Zf vector (Promega, Madison, Wis.) in which the polylinker from EcoRI to SacI had been destroyed. The targeting vector was made by inserting the first loxP site into the EcoRI site of a region 1 kb upstream of exon 2. This exon encodes the DNA-binding domain of PPAR␥. The first loxP site was inserted with a BamHI site in order to develop a means to genotype for the inclusion of this loxP site during homologous recombination. Insertion and orientation of the linker were confirmed by sequencing. A 2-kb SacI fragment containing a neomycin resistance cassette (neo) flanked by two loxP motifs was inserted into the SacI site located 0.75 kb downstream of exon 2. This fragment was cloned such that all three loxP sites were in the same orientation. The targeting vector contained 4-kb of homologous DNA upstream of the first loxP site and 2 kb of homologous DNA downstream of the loxP-neo-loxP cassette site. Finally, a thymidine kinase gene cassette was inserted into the SalI site of the polylinker. ES cells (RW4; Genome Systems) were electroporated with the linearized targeting construct and maintained on subconfluent embryonic fibroblasts. G418-resistant ES cell colonies were picked and expanded. The ES cells were scored for homologous recombination by Southern blotting. One (out of 264 ES cells screened) homologous recombinant was identified with a flanking probe (3Ј-probe; Fig. 1B ). The targeted ES cells were injected into C57BL/6 blastocysts, and the blastocysts were transferred into pseudopregnant NIH Swiss mice. Highly chimeric male mice were bred with C57BL/6 females to generate heterozygous loxP-targeted/wildtype (t/ϩ) mice. Deletion of the neomycin cassette in vivo was achieved by crossing the mice with an EIIaCre transgenic line (46) . The neomycin cassette deleted heterozygous mice carrying one floxed (fl; for flanked by loxP) and one wild-type allele were bred with homozygous MX-Cre mice (44 macrophages. mice were injected intraperitoneally with 250 l of pIpC (2.5 mg/ml in isotonic saline; Sigma) on days 1, 4, and 7. On day 10, mice were injected intraperitoneally with 2 ml of 3% thioglycolate solution (Becton Dickinson, Cockeysville, Md.). On day 14, peritoneal macrophages were harvested by injecting 10 ml of ice-cold phosphate-buffered saline with an 18-gauge needle into the peritoneal cavity and withdrawing the fluid with a 21-gauge needle and then repeating the procedure. After centrifugation at 1,000 ϫ g for 10 min, cells were resuspended in RPMI medium containing 10% fetal bovine serum and penicillin-streptomycin and then plated onto 150-mm petri dishes (Becton Dickinson Labware, Franklin Lakes, N.J.). After incubation of the cells at 37°C for 4 h, cells were further cultured in media containing the specified ligand or vehicle for 24 h.
Southern blot analysis. Genomic DNA was isolated from peritoneal macrophages by using a Wizard genomic DNA purification kit (Promega) according to the manufacturer's protocol. It was then digested with BamHI, subjected to electrophoresis on a 0.6% agarose gel, and transferred to GeneScreen Plus Hybridization Transfer membranes (NEN Life Sciences, Boston, Mass.). A 0.6-kb DNA fragment (SalI-EcoRI) derived from intron 2 of the PPAR␥ gene (3Ј-probe) and DNA fragments derived from exon 2 and neo (exon 2 probe and neo probe, respectively) were used as probes.
RNase protection assay. The RNA protection assay was performed by using RPAIII (Ambion, Austin, Tex.) according to the manufacturer's instructions. Antisense cRNA probes of PPAR␥ were prepared by using a MAXIscript kit from a clone containing exons 1 and 2 of the PPAR␥ gene. The clone was prepared by PCR with primers tagged with 5Ј-BamHI and 3Ј-EcoRI sites, and the PCR products were inserted into 5Ј-BamHI and 3Ј-EcoRI sites of the pTRiamp18 vector (Ambion). PCR was performed with the following primer sets: 5Ј-ACCTCTCCGTGATGGAAG-3Ј (forward) and 5Ј-GGTGGAGATGCAGG TTC-3Ј (reverse). Antisense riboprobes for ␤-actin were prepared from DNA provided with the RPAIII kit.
Northern blot analysis. Total RNA was isolated from thioglycolate-elicited macrophages of mice by the acidic guanidine isocyanate-phenol-chloroform extraction method by using the Ultraspec RNA Isolation System (Biotecx Laboratories, Houston, Tex.). Total RNA was quantitated by optical densitometry at 260 nm and subjected to electrophoresis on a 1.0% agarose gel containing 7% formaldehyde in 20 mM morpholinepropanesulfonic acid-8 mM sodium acetate-1 mM EDTA buffer (pH 7.0) and transferred to GeneScreen Plus Hybridization Transfer membranes (NEN Life Sciences). The cDNA probes used for Northern blotting included PPAR␥ (17) and LPL (36) . Probes for CD36, LXR␣, ABCA1, ABCG1, and apoE cDNA were amplified from a mouse liver cDNA library by using gene-specific primers and cloned into pCR TOPO II (Stratagene, La Jolla, Calif.). The identity of the probes was confirmed by nucleotide sequencing. The intensities of hybridizing mRNAs were quantitated by using ImageQuant and normalized to levels of ␤-actin mRNA.
Western blot analysis. Nuclear extracts from cultured macrophages were isolated according to the protocols provided with NE-PER Nuclear and Cytoplasmic Extraction Reagents kit (Pierce, Rockford, Ill.). Hepa-1 cells (2 ϫ 10 5 ) were transfected with 200 ng of an expression vector for PPAR␥1, pSG5-PPAR␥ (provided by Walter Wahli, Université de Lausanne, Lausanne, Switzerland), by lipofection according to the protocols provided with LipofectAMINE Reagent (Gibco-BRL, Grand Island, N.Y.). Protein contained in the nuclear extracts of macrophages or total protein of Hepa-1 cells was assayed by the BCA protein assay (Pierce Chemical Co., Rockford, Ill.). Then, 10 g of total protein from Hepa-1 cells and 10 g of protein from nuclear extracts of macrophages were subjected to electrophoresis on a 4 to 15% Tris-HCl gradient gel (Bio-Rad, Hercules, Calif.), transferred to Immobilon-P membranes (Millipore, Bedford, Mass.), and probed according to the manufacturer's recommendations with anti-PPAR␥ antibodies (E-8 and H-100; Santa Cruz Biotechnology, Inc., Santa Cruz, Calif.) as indicated. Detection of immunoreactive proteins was done by an enhanced chemiluminescence blot detection system (Amersham, Inc., Arlington Heights, Ill.).
Measurement of plasma lipids and lipoproteins. Total cholesterol and triglyceride concentrations (Sigma), as well as free cholesterol and phospholipids (Wako, Osaka, Japan), were measured in 12-l aliquots of plasma by using commercial kits and the Hitachi 911 automated chemistry analyzer (Boehringer Mannheim, Indianapolis, Ind.). Lipoproteins from pooled plasma samples (100 l) were separated by gel filtration by using two Superose 
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Piscataway, N.J.). Mouse apoA-I, apoA-II, apoE, and apoB were identified by Western blotting as previously described (31) . Cholesterol loading and efflux. Peritoneal macrophages were pretreated with the indicated ligands [troglitazone, 22(R)-hydroxycholesterol (22-HC), dexamethasone, or DMSO] and thereafter every 24 h in serum-free medium containing 0.1% albumin. The cells were cholesterol loaded by incubation with oxLDL (50 g/ml containing [ 3 H]cholesterol). After a 24-h incubation period, the cells were washed twice with phosphate-buffered saline, and fresh medium containing HDL (50 g/ml) or not was added for 24 h. The radioactivity of 3 H was measured in centrifuged media as well as in cellular lipids extracted with hexane-isopropanol. The total radioactivity in cells and media corresponds to the cellular loading of cholesterol from oxLDL. HDL-specific [ 3 H]cholesterol efflux was measured as the fraction of total radiolabeled cholesterol appearing in the media in the presence of HDL after subtraction of values for HDL-free media (18) .
RESULTS
Generation of a conditional allele of the PPAR␥ gene. A targeting vector containing three loxP sites in the same orientation was constructed (Fig. 1A) . The first loxP site (with an artificial BamHI site) was inserted into an EcoRI site of a region 1 kb upstream of exon 2 that encodes the DNA-binding domain of PPAR␥. A 2-kb SacI fragment containing a neomycin resistance cassette (neo) flanked by two loxP motifs (flneo-fl) was inserted into the SacI site located 0.75 kb downstream of exon 2. Finally, a thymidine kinase gene cassette was inserted into the SalI site of the polylinker. After standard electroporation and culture of ES cells, one homologous recombinant (out of 264 ES cells screened; ES clone 59) was identified by Southern blotting of genomic DNA by using a probe derived from exon 2 (Fig. 1B) . Similar results were obtained by using a flanking probe designated 3Ј-probe (data not shown). The targeted ES cells were injected into C57BL/6 blastocysts, which were then transferred into pseudopregnant NIH Swiss mice. Highly chimeric male mice were bred with C57BL/6 females to generate heterozygous loxP-targeted/wildtype (t/ϩ) mice. Breeding of these offspring resulted in either wild-type (ϩ/ϩ) or t/ϩ mice, with no t/t mice, indicating that the neo cassette inactivated the PPAR␥ gene, resulting in embryonic lethality. This is in agreement with other studies showing that disruption of the PPAR␥ gene is lethal (3, 42, 73) . To circumvent this problem, the neomycin cassette was removed in vivo by crossing the t/ϩ mice with a EIIaCre transgenic line (31, 46) . Recombination events were analyzed by Southern blotting of the tail DNA with the 3Ј-probe (Fig. 1C) and exon 2 probe (identical results not shown). Deletion of the neomycin cassette in the same tail DNA samples was confirmed by Southern blotting with a neo probe (Fig. 1D ). Mice that were heterozygous for the floxed PPAR␥ allele (PPAR␥ fl/ϩ ) were bred with homozygous MXCre ϩ mice (44) . Heterozygous offspring for the targeted PPAR␥ gene that were either hemizygous for the Cre transgene (PPAR␥ fl/ϩ MXCre ϩ ) or lacking Cre (PPAR␥ fl/ϩ MXCre Ϫ ) were interbred. This breeding scheme yielded mice that were homozygous for the PPAR␥-floxed allele and either hemizygous for or lacking the MX-Cre transgene (PPAR␥-MXCre ϩ and PPAR␥-MXCre Ϫ , respectively). These mice were subsequently interbred to generate littermates of the same genotypes. All breedings subsequent to the removal of the neo cassette resulted in a distribution of the genotypes of offspring that followed the predicted Mendelian frequency (data not shown), suggesting that neither the floxed PPAR␥ allele nor the MX-Cre transgene contributed to prenatal lethality.
Conditional deletion of exon 2 of the PPAR␥ gene in peritoneal macrophages. Treatment of PPAR␥-MXCre ϩ mice with pIpC, which was shown to activate the MX promoter by stimulating the production of alpha and beta interferon (13, 83) , results in a nearly complete deletion of the floxed exon 2 in thioglycolate-elicited peritoneal macrophages (Fig. 2) . A partial deletion of the floxed exon 2 was detected in the macrophages of saline-treated PPAR␥-MXCre ϩ mice. To test the possibility that spontaneous deletion resulting from constitutive expression of the MX-Cre transgene had occurred, Southern blot analysis of genomic DNA of macrophages from untreated PPAR␥-MXCre ϩ mice was performed. Deletion of exon 2 was shown to occur in a portion of the macrophage population, as indicated by the presence of a 8-kb hybridizing band which represents a deleted PPAR␥ allele, suggesting that there is some spontaneous deletion or "leakiness" associated with the MX-Cre transgene (Fig. 2B) . To determine the extent, the intensities of the hybridizing bands representing the PPAR␥ floxed and deleted alleles (10-and 8-kb hybridizing bands, respectively) were quantitated. Values were normalized to intensities of the hybridizing DNA bands with PPAR␥ fl/Ϫ tail DNA, which represents a theoretical 1:1 ratio of floxed to deleted allele (Fig. 2B) . The results show that the intensities of the PPAR␥ floxed and deleted allele are in a 3.4 to 1 ratio, respectively, indicating that the majority (77.2%) of thioglycolate-elicited macrophages from pretreated PPAR␥-MXCre ϩ mice were differentiated in the presence of an intact gene for PPAR␥. As expected, neither pIpC nor saline treatment re- (Fig. 2A) . Nearly complete disruption of the PPAR␥ gene was also demonstrated in the liver (not shown), a finding consistent with the results of earlier studies with the MX-Cre transgene in which a nearly complete pIpC deletion was shown in the liver (a tissue in which PPAR␥ is not well expressed) and macrophages (44, 68, 72) . Based on these results, macrophages derived from pIpC-treated PPAR␥-MXCre ϩ mice (designated as PPAR␥-deficient macrophages) and pIpC-treated PPAR␥-MXCre Ϫ mice (control macrophages) were used in the following studies.
Disruption of the PPAR␥ gene results in a truncated PPAR␥ mRNA transcript. Northern blot analysis of total macrophage RNA with a PPAR␥ cDNA probe revealed a marked reduction in steady-state levels of a truncated PPAR␥ mRNA levels in macrophages derived from PPAR␥-MXCre ϩ mice relative to control PPAR␥-MXCre Ϫ mice (both pIpC and saline treatments) (Fig. 3A) . It did not appear that treatment of either PPAR␥-deficient and control macrophages with troglitazone, 22-HC, or dexamethasone in vitro significantly altered PPAR␥ mRNA levels. The loss of full-length PPAR␥ mRNA and the presence of a truncated PPAR␥ mRNA product, a finding consistent with the expected size based upon Cre recombination, was confirmed in PPAR␥-deficient macrophages by using RNase protection assays (Fig. 3B) . As expected, based on the partial deletion of the PPAR␥ gene in the macrophages of saline-treated PPAR␥-MXCre ϩ mice ( Fig. 2A) , both fulllength and truncated PPAR␥ transcripts were detected (Fig.  3B) . Using a ␤-actin riboprobe to normalize for the amount of total RNA, PPAR␥-deficient macrophages were shown to exhibit significantly lower levels of PPAR␥ transcript, thus suggesting the possibility that the truncated transcript is inherently less stable than wild-type PPAR␥ mRNA.
Disruption of the PPAR␥ gene results in the loss of PPAR␥ protein in macrophages. To determine whether disruption of the PPAR␥ gene results in a loss of PPAR␥ protein or the production of a truncated mutant form of the protein, nuclear extract proteins from peritoneal macrophages were analyzed by Western blotting. The results with a primary antibody raised against a peptide mapping at the carboxy terminus of PPAR␥ of human origin that is identical to the corresponding mouse sequence (E-8 PPAR␥ antibody) reveal that a 53-kDa protein product is expressed in thioglycolate-elicited macrophages from pIpC-treated PPAR␥-MXCre Ϫ but not PPAR␥-MXCre ϩ mice (Fig. 4A ). This protein is consistent in size with the PPAR␥1 protein and with the protein product expressed in Hepa-1 cells transfected with an expression vector for PPAR␥1 (pSG5-PPAR␥1 cDNA). As expected, the putative truncated PPAR␥ protein product, which has an expected size of 10 kDa, was not detected by the E-8 antibody (Fig. 4A) . Similar results were obtained with the H-100 primary antibody, a PPAR␥ antibody that was raised against a recombinant protein corresponding to amino acids 6 to 105 of the PPAR␥ protein and is therefore expected to recognize both the wild-type and putative truncated form of this protein. A 53-kDa protein product that is consistent in size with the PPAR␥ protein was expressed in macrophages from pIpC-treated PPAR␥-MXCre Ϫ mice but not in macrophages from pIpC-treated PPAR␥-MXCre ϩ mice (Fig. 4B) . Likewise, the expected translation product of PPAR␥ mRNA lacking exon 2, which is ca. 10 kDa, does not appear on Western blotting, perhaps due to increased instability of prematurely terminated proteins (Fig. 4B) .
Disruption of the PPAR␥ gene results in the loss of PPAR␥ activity in macrophages. To evaluate whether disruption of the PPAR␥ gene results in a functional deficiency in PPAR␥ activity, the expression of the known PPAR␥ target gene, CD36, was examined in PPAR␥-deficient and control macrophages. 
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Consistent with previous findings (15, 56) , the expression of the gene encoding CD36 was induced by troglitazone in control macrophages but not in PPAR␥-deficient macrophages (Fig.  5 ). Basal levels of CD36 were also significantly lower in PPAR␥-deficient macrophages relative to control macrophages. A gene dosage effect appeared to be present, since a less robust induction of CD36 mRNA by troglitazone was observed in macrophages derived from saline-treated PPAR␥-MXCre ϩ mice, which have a partial deletion of the PPAR␥ gene (Fig. 5) . Neither 22-HC nor dexamethasone significantly altered CD36 expression in both PPAR␥-deficient or control macrophages. Together, these results indicate that targeted disruption of the PPAR␥ gene leads to a functional loss of PPAR␥ activity in primary peritoneal macrophages, which is consistent with the loss of PPAR␥ protein. Furthermore, the observation that troglitazone stimulated CD36 gene expression in control macrophages, which contain a homozygous floxed allele for the PPAR␥ gene, indicates that the presence of loxP sites within introns 1 and 2 of the PPAR␥ gene does not interfere with the activity of the PPAR␥ protein.
To examine whether PPAR␥ plays a role in regulating the expression of other scavenger receptors that bind modified lipoproteins, SR-A and SR-BI mRNA levels were determined in PPAR␥-deficient and control macrophages. Consistent with previous studies (15, 16) , however, the levels of SR-A and SR-BI mRNA were not substantially altered in response to the disruption of the PPAR␥ gene or by treatment with troglitazone, 22-HC, or dexamethasone in both PPAR␥-deficient and control macrophages (data not shown).
PPAR␥ has a critical role in the regulation of the LPL gene in primary macrophages. Associations between macrophagederived LPL and the development of atherosclerosis have been described (1, 2, 90) . This, coupled with the fact that the LPL gene is an established target of PPAR␥ in several other tissues, including liver and adipocytes (78) , prompted us to examine LPL expression in primary macrophages. Similar to CD36, a striking reduction in basal and troglitazone-induced expression of the LPL gene was observed in PPAR␥-deficient macrophages relative to controls (Fig. 5) , suggesting that the LPL gene is a target of PPAR␥ in macrophages. Interestingly, 22-HC and dexamethasone were shown to enhance and suppress, respectively, the expression of LPL independent of the PPAR␥ gene disruption (Fig. 5) . FIG. 4 . Western blot analysis of nuclear extracts from macrophages of pIpC-treated PPAR␥-MXCre ϩ mice and similarly treated PPAR␥-MXCre Ϫ mice. A total of 10 g of protein from nuclear extracts of macrophages and 10 g of total protein from Hepa-1 cells transfected with an expression vector for PPAR␥1 (pSG5-PPAR␥ cDNA) were subjected to electrophoresis on a 4 to 15% Tris-HCl gradient gel (Bio-Rad), transferred to Immobilon-P membranes (Millipore), and probed as recommended by the manufacturer with anti-PPAR␥ antibodies (Santa Cruz Biotechnologies) specific for the N terminus (E-8, PPAR␥ antibody) (A) and the C terminus (H-100, PPAR␥ antibody) (B) of the PPAR␥ protein. Detection of immunoreactive proteins was done by using an enhanced chemiluminescence blot detection system (Amersham). Regulation of reverse cholesterol transport by PPAR␥ at the level of gene expression. PPAR␥ was recently shown to induce the expression of the cholesterol transporter, ABCA1, via a transcriptional cascade involving LXR␣ (16, 21, 79, 91) . Given the importance of the ABC family of transporter proteins in the regulation of cholesterol efflux in macrophages and its possible association with the development of foam cells of atherosclerotic plaques, components of the PPAR␥-LXR␣-ABCA1 pathway were examined at the level of gene expression in primary macrophages. In agreement with this pathway, troglitazone induced steady-state levels of LXR␣ mRNA in control macrophages, an effect which was absent in PPAR␥-deficient macrophages (Fig. 6 ). Basal levels of LXR␣ mRNA expression were also lower in PPAR␥-deficient macrophages, a finding consistent with reductions in basal levels of PPAR␥ expression. The LXR␣ ligand, 22-HC, slightly increased LXR␣ mRNA levels in control but not PPAR␥-deficient macrophages (Fig. 6) . To determine whether PPAR␥-mediated regulation of LXR␣ extended to members of the ABC family of cholesterol transporters in macrophages, ABCG1 and ABCA1 gene expression levels were examined. Basal and troglitazoneinducible expression of the ABCG1 gene was found to be significantly inhibited in PPAR␥-deficient macrophages relative to controls (Fig. 6) , a finding consistent with the finding that lipid induction of ABCG1 (and ABCA1) expression in macrophages depends on LXRs (45, 70, 91, 92) . Likewise, basal expression of ABCA1 was slightly reduced in PPAR␥-deficient macrophages. Unexpectedly, however, troglitazone inhibited ABCA1 gene expression in both PPAR␥-deficient and control macrophages, an effect which sharply contrasts the results of previous studies (16, 18) and the observed ABCG1 expression profiles (Fig. 5) . The demonstration that 22-HC was capable of inducing ABCA1 and ABCG1 gene expression in PPAR␥-deficient and control macrophages confirmed that the LXR signaling pathways downstream of PPAR␥ were intact in both macrophage populations.
To determine whether the observed effects of troglitazone extend to other members of the TZD family of PPAR␥ agonists, the effect of rosiglitazone, ciglitazone, and pioglitazone on the expression of the gene encoding ABCA1 was examined. Unlike troglitazone, however, these TZDs were shown to have minimal effect on the expression of the gene encoding ABCA1 in both PPAR␥-deficient and control macrophages (Fig. 7) . To confirm the efficacy of these ligands, the expression of the gene encoding CD36 was also examined. As expected, each of these TZDs (rosiglitazone, ciglitazone, and pioglitazone) was capable of stimulating CD36 gene expression in control but not PPAR␥-deficient macrophages (Fig. 7) . It therefore appears that troglitazone has effects on ABCA1 gene expression that are unique for the TZD family of PPAR␥ agonists.
Reduction in basal levels of apoE gene expression in macrophages and plasma of pIpC-treated PPAR␥-MXCre ؉ mice. apoE may be an important determinant of atherosclerosis and a regulator of cholesterol efflux in macrophages (5, 6, 22, 24, 41, 54, 66, 96, 97) . Consistent with the finding that the apoE gene is an LXR␣ target (45) , basal expression of the gene encoding apoE was significantly attenuated in PPAR␥-deficient macrophages relative to controls (Fig. 8A) , while 22-HC was shown to induce apoE gene expression in a PPAR␥-independent manner, an effect that was even more pronounced after dexamethasone treatment.
It is also noteworthy that pIpC-treated PPAR␥-MXCre ϩ mice exhibited a significant reduction of apoE (Ϫ30% by densitometric analysis) in plasma, mostly due to decreased HDL , and the total macrophage RNA (10 g) was denatured and electrophoresed in formaldehyde-containing 1% agarose gels, blotted onto nylon membranes, and probed with the indicated cDNA probes for ABCA1, CD36, and ␤-actin. The intensities of hybridizing mRNA bands were quantitated and normalized to ␤-actin mRNA. The numbers represent signal intensities relative to pIpCtreated Cre Ϫ macrophages (lane 1).
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on February 23, 2013 by PENN STATE UNIV http://mcb.asm.org/ apoE levels (Fig. 8B, inset) . The total cholesterol, phospholipid, triglyceride, and cholesterol ester levels in plasma were similar in pIpC-treated PPAR␥-MXCre ϩ mice and pIpCtreated controls (not shown), but in pIpC-treated PPAR␥-MXCre ϩ mice, FPLC analysis revealed a decrease in LDLcholesterol accompanied by a modest increase in HDLcholesterol (Fig. 8B) . The decrease in LDL-cholesterol was paralleled by a concomitant decrease in plasma apoB levels (Fig. 8B, inset) . The possibility that PPAR␥ deficiency in tissues other than macrophages may have contributed to changes in the serum lipid profiles cannot be ruled out, since a nearly complete disruption of the PPAR␥ gene was also detected in liver (not shown). Indeed, the loss of even low levels of endogenous PPAR␥ expression in liver may play a significant role in altering the FPLC profile, given the importance of this organ in regulating lipoprotein metabolism in serum.
Disruption of the PPAR␥ gene results in reduced basal levels of cholesterol efflux from macrophages. To examine possible roles of PPAR␥ in regulating cholesterol efflux in primary macrophages, cholesterol efflux studies were performed. After disruption of the PPAR␥ gene, basal cholesterol efflux from cholesterol-loaded macrophages to HDL was significantly reduced (Fig. 9) . Paradoxically, and in sharp contrast to the results of previous cholesterol efflux studies (15, 18, 56) , troglitazone lowered cholesterol efflux to HDL in both PPAR␥-deficient and control macrophages (Fig. 7) . On the other hand, 22-HC was shown to stimulate cholesterol efflux in both PPAR␥-deficient and control macrophages. In fact, the levels of cholesterol efflux from PPAR␥-deficient and control macrophages induced by 22-HC treatment were similar, indi- cating that the effects of LXR␣ signaling on cholesterol efflux can compensate for a lack of PPAR␥ activity. These results are in agreement with our observation that troglitazone inhibited, whereas 22-HC induced, the expression of the gene encoding the cholesterol transporter ABCA1 in both macrophage populations. Together, these results point to a critical role of PPAR␥ in the regulation of basal cholesterol efflux in macrophages and imply that troglitazone may have effects on cholesterol homeostasis that are independent of PPAR␥.
DISCUSSION
This report describes the development of a viable PPAR␥ conditional gene knockout mouse that circumvents the embryonic lethality associated with disruption of the PPAR␥ gene. Introduction of the MX-Cre transgene into this mouse line allowed for the pIpC-inducible deletion of the targeted PPAR␥ exon 2 in primary peritoneal macrophages and corresponding loss of the full-length PPAR␥ mRNA transcript and protein. Significant reductions in both basal and troglitazoneinducible expression of the known PPAR␥ macrophage target genes, CD36 (87) and LXR␣ (16) , were shown, indicating a loss of PPAR␥ function and suggesting that these macrophages may be useful in studying possible roles of PPAR␥ in macrophage functions relevant to atherosclerosis. The changes in basal expression of PPAR␥ target genes in PPAR␥-deficient mice also imply the production of endogenous ligands for PPAR␥ and its heterodimeric partner, RXR␣. Stimulation of PPAR␥ target genes by troglitazone alone provides further evidence for the presence of sufficient levels of endogenous RXR ligands to support PPAR␥ signaling in primary macrophages.
The demonstration that PPAR␥ is required for basal and troglitazone-inducible expression of the gene encoding LPL represents a novel finding suggesting that the LPL gene (which contains a PPRE in its promoter) is a PPAR␥ target in macrophages, as has been shown in other tissues, including liver and adipose tissue (78) . The PPAR␥-independent induction of LPL gene expression by 22-HC and suppression by dexamethasone also represent novel findings that may have important implications. Indeed, the transplantation of LPL-null bone marrow into wild-type C57BL/6 mice (90) or LDLr-null mice (1) reduced atherosclerotic lesion size, whereas the in vivo expression of macrophage-derived LPL promotes foam cell formation and atherosclerosis (1, 2, 90) .
The marked reductions in basal and troglitazone-stimulated expression of the gene encoding ABCG1 in PPAR␥-deficient macrophages corresponded well with the LXR␣ expression profile and was consistent with previous studies (with LXR knockout mice) showing that LXR signaling pathways modulate ABCG1 (and ABCA1) expression in macrophages (45) . Based on these results, it is proposed that a PPAR␥-LXR␣-ABCG1 pathway is likely to present in macrophages, although the ABCG1 gene has yet to be established as a direct target of LXR␣. In addition to a direct transcriptional effect of PPAR␥ on LXR␣, PPAR␥ may also regulate ABC gene expression by enhancing the uptake of modified lipoproteins containing LXR␣ ligands through CD36, a possibility which remains to be examined. In contrast to the results of ABCG1, however, troglitazone inhibited the expression of the gene encoding ABCA1 in both PPAR␥-deficient and control macrophages, a reproducible result that was evident in the same RNA samples in which other PPAR␥ targets were shown to be induced. This result was rather surprising in light of the proposed PPAR␥-LXR␣-ABCA1 pathway and previous findings showing that PPAR␥ agonists were capable of inducing ABCA1 gene expression. However, other TZDs, including rosiglitazone, ciglitazone, and pioglitazone, have minimal effect on the expression of the gene encoding ABCA1 in both PPAR␥-deficient and control primary macrophages. It therefore appears that troglitazone has effects on ABCA1 gene expression that are unique for the TZD family of PPAR␥ agonists. Given that the expression of the ABCA1 gene is regulated by a number of factors, including cyclic AMP, serum deprivation in vitro, 9-cisretinoic acid, and various cytokines (76) , troglitazone may exert specific effects on ABCA1 gene expression through one or more of these factors, possibilities which remain to be examined. For example, troglitazone was shown to inhibit phorbol ester-induced tumor necrosis factor alpha release in a monocyte cell line, THP-1, whereas neither pioglitazone nor rosiglitazone had any effect (59) . The demonstration that 22-HC induced both ABCA1 and ABCG1 gene expression in both PPAR␥-deficient and control macrophages indicates that the suppression of ABCA1 by troglitazone is not likely to be the result of defective LXR signaling pathways.
The demonstration that basal levels of cholesterol efflux to HDL were lower in PPAR␥-deficient macrophages than control macrophages points to a critical role of PPAR␥ in modulating constitutive levels of cholesterol efflux in primary macrophages. The presence of functional LXR signaling pathways was again indicated by the fact that 22-HC not only induced both ABCA1 and ABCG1 gene expression but also promoted cholesterol efflux in both PPAR␥-deficient and control macrophages. The suppression of ABCA1 and HDL-specific cholesterol efflux by troglitazone in both PPAR␥-deficient and control primary macrophages was an unexpected finding that sharply contrasts with the results of previous cholesterol efflux studies with ES-cell derived macrophages (16) . Although the reasons for these differences are not entirely clear, it is noted that costimulation with the LXR␣ ligand, 22-HC, was required in that study to achieve maximal effects of PPAR␥ agonists on ABCA1 and ABCG1 gene expression, thus suggesting that endogenous ligands for LXR␣ in ES cell-derived macrophages were not in sufficient concentration to fully support the proposed PPAR␥-LXR␣-ABCA1 regulatory pathway. Moreover, differences in these results may be attributable to the use of primary macrophages in the present study. Indeed, others have reported that LXR or RXR ligands, but not the PPAR␥ ligand, rosiglitazone, induced ABCA1 expression and enhanced cholesterol efflux (20) in primary murine macrophages. Effects of PPAR␥ agonists on macrophages may also be species specific since they were shown to induce ABCA1 gene expression and enhance cholesterol removal from human primary macrophages (18) . An important consideration may pertain to the experimental conditions under which independent studies were performed. In the above study (18) , mononuclear cells from the blood of healthy normolipidemic donors were cultured for a period of 10 days, enough time to induce differentiation into macrophages. Since the expression of CD36 and apoE, two proteins believed to affect lipid flux in macrophages, VOL. 22, 2002 DEVELOPMENT OF PPAR␥ CONDITIONAL GENE KNOCKOUT MOUSE 2615 is highly upregulated during the conversion of monocytes to macrophages (4, 33) , the effects of PPAR␥ ligand stimulation on ABC expression and cholesterol efflux must be considered in the context of in vitro differentiated primary macrophages from monocytes. Other PPAR␥-independent effects of troglitazone have been reported (62) . Our results with troglitazone thus add to the growing list of PPAR␥-independent effects of PPAR␥ agonists, highlighted by the prostaglandin metabolite, 15d-PGJ 2 (74, 84, 89, 93) . It is becoming increasingly clear that a number of proteins not associated with the PPAR␥-LXR␣-ABCA1 pathway also play an important role in regulating cholesterol efflux in macrophages. Indeed, a recent study has provided evidence for the existence of a transcriptional repressor of ABCA1 gene expression, the zinc-finger protein 202, that significantly reduces HDL-mediated lipid efflux in macrophages (67) , although effects of troglitazone on this repressor have yet to be examined. Numerous studies have also shown that lack of macrophagederived apoE is sufficient to inhibit cholesterol efflux from macrophages and promote atherosclerosis (10, 26, 47, 52) . It is thus likely that the reduction in basal levels of expression of the gene encoding apoE contributed to the attenuation of cholesterol efflux in PPAR␥-deficient macrophages. This result is consistent with the finding that the apoE gene is a direct target of LXR␣ and LXR␤ in macrophages (45) , since constitutive levels of LXR␣ expression were reduced in PPAR␥-deficient macrophages. apoE insufficiency may have also contributed to the significant increase in atherosclerotic lesion size shown in LDLr-null mice transplanted with PPAR␥-null bone marrow (16), a possibility which remains to be examined. The lack of a robust induction of apoE by troglitazone in either PPAR␥-deficient or control macrophages may be related to a sharing of the regulatory control of apoE expression by both LXR␣ and LXR␤ since oxysterol induction of apoE was only partially compromised in LXR␣ Ϫ/Ϫ mice relative to LXR␣ Ϫ/Ϫ LXR␤ Ϫ/Ϫ double knockout mice (45) . Interestingly, dexamethasone was also shown to strongly stimulate apoE gene expression in macrophages in a PPAR␥-independent manner, pointing to a potential therapeutic use for glucocorticoids in protecting against the development of atherosclerosis. It is also noteworthy that pIpC-treated PPAR␥-MXCre ϩ mice exhibited a significant reduction of apoE (Ϫ30% by densitometric analysis) in plasma, mostly due to decreased HDL apoE levels (Fig. 8B, inset) . The attenuation of apoE expression in serum may be the result of lowered macrophage LPL expression, since transplantation of LPL Ϫ/Ϫ bone marrow into wild-type mice was shown to result in a 50% reduction in apoE expression in serum relative to control mice (90) . Although plasma lipid levels in pIpC-treated PPAR␥-MXCre ϩ mice were similar relative to pIpC-treated control mice, FPLC analysis revealed a decrease in LDL-cholesterol and apoB accompanied by a modest increase in HDL-cholesterol. Since the PPAR␥ gene was also disrupted in the liver (not shown), an organ which plays an important role in the regulation of serum lipoproteins, it must be emphasized that the possibility that PPAR␥ deficiency in the liver contributed to the observed changes in lipoprotein-associated cholesterol levels cannot be ruled out, despite the fact that PPAR␥ is expressed at very low levels in the liver. These results are consistent with the fact that little changes in plasma lipid levels were observed in studies in which the human apoE transgene was expressed in the macrophages of apoE Ϫ/Ϫ mice (7) and in which apoE Ϫ/Ϫ macrophage stem cells were transplanted into apoE ϩ/ϩ mice (26), despite major changes in atherosclerotic plaque lesion size.
Interest in the pleiotropic effects of TZDs stems largely from their widespread use in diabetic patients. The suppressive effects of troglitazone on ABCA1 expression and cholesterol efflux carries with it the implication that troglitazone promotes the formation of foam cells associated with atherosclerotic plaques by inhibiting cholesterol removal from macrophages independently of the expression of PPAR␥. The PPAR␥-independent inhibitory effect of troglitazone on ABCA1 expression probably masks or reduces PPAR␥-dependent effects that are likely to be clinically beneficial. It will therefore be important to determine whether these effects are seen in human cells and whether PPAR␥-independent effects on cholesterol efflux are observed for other classes of PPAR␥ agonists. Clearly, the development of PPAR␥ ligands that do not have this property would be desirable from a clinical standpoint. Numerous whole-body effects of troglitazone on insulin sensitivity, blood pressure, hyperlipidemia, and oxidation of LDL have been reported (30, 60) . Further, TZDs were shown to have beneficial effects on local events in the artery wall, including reducing carotid thickness in humans, neointimal formation following balloon injury in rats, and macrophage recruitment to the artery wall in atherosclerosis-susceptible apoE-deficient mice (49, 55, 65, 80) . These effects preclude us from making accurate conclusions regarding the long-term effects of TZDs on atherosclerosis in animals and humans based solely on cholesterol flux in macrophages. The introduction of the PPAR␥ conditional allele into atherogenic backgrounds including LDLr-null and apoE-null mouse models should further aid in our understanding of the effects of PPAR␥ signaling and TZDs on atherogenesis. In particular, an apoE-null background may help to separate the putative effects of apoE from other PPAR␥-mediated effects on cholesterol efflux or atherosclerosis.
Taken together, this study describes the development of a conditional PPAR␥ knockout mouse. Based on this in vivo model of PPAR␥ deficiency, evidence is provided here indicating that PPAR␥ plays a critical role in controlling the expression of a network of genes that mediate cholesterol efflux from cells and cholesterol transport in plasma.
